公开(公告)号：US10150728B2

公开(公告)日：2018-12-11

申请号：US15029031

申请日：2014-10-17

申请人： Shionogi & Co., Ltd.

发明人： Naotake Kobayashi ,  Kentarou Asahi ,  Yutaka Tomida ,  Masahide Ohdan ,  Masataka Fumoto ,  Yoshikazu Sasaki ,  Kana Kurahashi ,  Takatsugu Inoue ,  Tomomi Urabe ,  Yuji Nishiura ,  Masafumi Iwatsu ,  Keisuke Miyazaki ,  Naoki Ohyabu ,  Toshihiro Wada ,  Manabu Katou

IPC分类号： C07C233/22 ,  C07C233/18 ,  C07C233/31 ,  C07C275/10 ,  C07D403/12 ,  C07D401/14 ,  C07D231/56 ,  C07D401/12 ,  C07D403/14 ,  C07D239/80 ,  C07D413/12 ,  C07D241/18 ,  C07D417/12 ,  C07D261/20 ,  C07D267/14 ,  C07D277/20 ,  C07D277/34 ,  C07D213/64 ,  C07D213/69 ,  C07D263/56 ,  C07D277/64 ,  C07D277/68

摘要： The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound.A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is —O—(CR6R7)m- etc., -L2- is —O—(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc.

公开(公告)号：US10335401B2

公开(公告)日：2019-07-02

申请号：US16061155

申请日：2016-12-21

申请人： Shionogi & Co., Ltd.

发明人： Yuji Nishiura ,  Kana Kurahashi ,  Naoki Ohyabu ,  Yoshikazu Sasaki

IPC分类号： A61K31/444 ,  C07D405/14 ,  C07D413/14 ,  A61K31/435 ,  C07D401/04 ,  C07D409/14 ,  C07D211/86 ,  A61P9/10 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61K31/4439 ,  A61K31/5377

摘要： The present invention relates to a compound represented by Formula (I): wherein X is, for example, C(═O); Z is, for example, C(═O); L is, for example, a single bond; A is, for example, aromatic carbocycle; R is, for example, R6 or B; R2 is, for example, hydrogen; R3 is, for example, substituted or unsubstituted alkyl; R4a is, for example, hydrogen; R4b is, for example, hydrogen; R5 is, for example, halogen; R6 is, for example, halogen; R7a is, for example, hydrogen; R7b is, for example, hydrogen; R8 is, for example, hydrogen; R9 is, for example, hydrogen; m is 0 to 5; n is 0 to 5; and p is 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US10233156B2

公开(公告)日：2019-03-19

申请号：US15557992

申请日：2016-03-30

申请人： Shionogi & Co., Ltd.

发明人： Naoki Ohyabu ,  Kana Kurahashi ,  Yuji Nishiura ,  Manabu Katou ,  Keisuke Miyazaki ,  Yoshikazu Sasaki ,  Toshihiro Wada ,  Masafumi Iwatsu

IPC分类号： C07D235/04 ,  C07D263/56 ,  C07D235/26 ,  C07D403/12 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/506 ,  C07D401/04 ,  C07D401/12 ,  C07D235/28 ,  C07D403/04 ,  C07D405/12 ,  C07D471/04 ,  C07D493/04 ,  A61P3/06 ,  A61P3/08 ,  A61P9/00

摘要： The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound.A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; —L1— is —O—(CR6R7)m— or the like; —L2— is —O—(CR6R7)n— or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.